Wedbush Maintains Outperform on Spyre Therapeutics, Lowers Price Target to $120
Benzinga Newsdesk 22 hours ago
Analyst RatingsNewsPrice Target
Wedbush analyst David Nierengarten maintains Spyre Therapeutics (NASDAQ:SYRE) with a Outperform and lowers the price target from $123 to $120.
Wedbush analyst David Nierengarten maintains Spyre Therapeutics (NASDAQ:SYRE) with a Outperform and lowers the price target from $123 to $120.